Skip to main content

Page last checked

Goal

Peptides for sexual function

People buy two peptides for libido and erections. One carries an FDA approval whose label rules out the group buying it most.

Source: Based on 2 compound guides · checked 2026-08-12

That contradiction is the whole page. PT-141 is a real approved medicine with a real trial program behind it. FDA approved it for one group, and a different group buys it. The label is unusually explicit about this.

The second row is university physiology research. Nobody designed it to treat anyone. Each row gives the practice, then the page.

At a glance

Compounds covered

2

With published human dosing

2 of 2

Approved or being tested for this

1

No human evidence for this goal

0

Two compounds, and who the evidence is about

Read the right column for the population studied and the route used. On both rows those differ from the people buying it and the way they use it.

2 compounds coveredsources shown in each row
Compounds people take for this purpose, why they use them, what human research has measured, and where the evidence comes from.
CompoundWhat people take it forWhat research showsEvidence
PT-141VyleesiBought mostly by men, for erections and desire, usually as a research powder rather than the approved product.FDA-approved for thisApproved in 2019 as Vyleesi, for premenopausal women with low sexual desire. The same label excludes postmenopausal women and rules out use to improve sexual performance. The approved dose is 1.75 mg as needed, never more than once in 24 hours, and no more than eight doses a month.FDA labelDose from the FDA-approved label
Kisspeptin-10Sold for libido, for fertility and for raising testosterone, on its position upstream of the sex hormones.Measured in a human studyThe human work is physiology research in groups of four to six people, run to map the circuit rather than to treat anyone. Into a vein it lifted luteinising hormone in men within half an hour. Under the skin — the route these vials are sold for — it moved neither hormone in the women studied.limited human dataDose from a human trial · no FDA label

1 has an FDA-approved product for this purpose. 1 rests on a human study that measured something in this goal.

An approval that excludes its own buyers

FDA approved Vyleesi for premenopausal women with acquired, generalized low sexual desire. Its label then does two further things that matter here. It excludes postmenopausal women, and it rules out use to improve sexual performance.

Those two exclusions together describe most of the people buying PT-141 today. The approval is real and so are the trials behind it. A reader who takes it as reassurance is reading a document about somebody else.

There is a second gap in the same place. The approved product is a ready-filled autoinjector holding 1.75 mg in solution. Its label contains no powder vial and no mixing step anywhere. Research-grade PT-141 sold as a powder is not that product, and no approved label stands behind it. In the trials that produced the approval, 18% of participants stopped because of a reaction.

The route that was sold is the route that did nothing

Kisspeptin-10 supplies the clearest route lesson on the site. Given into a vein it produced a clear hormone response in men. Under the skin, the way sellers ship these vials, it produced no measurable rise in either gonadotropin in the women studied.

That is not an absence of data. It is data pointing the other way for the exact route people use. Those studies picked per-kilogram quantities to probe a hormone circuit under ethics approval. None of them set a dose for anyone.

Where to go next

Every purpose covered this way is listed on the index of goals people buy peptides for.

3primary sources, each with the day we read it — open the documents used on this page